Privia Health Group, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: PRVA · Form: DEF 14A · Filed: Apr 4, 2024 · CIK: 1759655

Privia Health Group, Inc. DEF 14A Filing Summary
FieldDetail
CompanyPrivia Health Group, Inc. (PRVA)
Form TypeDEF 14A
Filed DateApr 4, 2024
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Corporate Governance, Privia Health

TL;DR

<b>Privia Health Group, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance for the fiscal year ending December 31, 2023.</b>

AI Summary

Privia Health Group, Inc. (PRVA) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Privia Health Group, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 950 N. Glebe Rd., Suite 700, Arlington, VA 22203. The filing includes information related to executive compensation for fiscal years 2021, 2022, and 2023. Specific details regarding stock awards, option awards, and forfeited/vested awards for key executives are presented.

Why It Matters

For investors and stakeholders tracking Privia Health Group, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation packages, allowing them to make informed voting decisions on related proposals. The DEF 14A outlines the company's governance practices and executive remuneration, which can impact investor confidence and the company's stock performance.

Risk Assessment

Risk Level: low — Privia Health Group, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational distress.

Analyst Insight

Review the executive compensation details and any shareholder proposals within the DEF 14A to understand potential impacts on corporate governance and shareholder value.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Reporting period)
  • 2024-04-04 — Filing Date (Date of submission)
  • 2021, 2022, 2023 — Fiscal Years Covered (Executive compensation data)

Key Players & Entities

  • Privia Health Group, Inc. (company) — Filer name
  • DEF 14A (filing) — Form type
  • 0001193125-24-087256 (filing) — Accession number
  • 950 N. Glebe Rd., Suite 700, Arlington, VA 22203 (address) — Business address
  • Mr. Shawn Morris (person) — Executive mentioned in compensation tables

FAQ

When did Privia Health Group, Inc. file this DEF 14A?

Privia Health Group, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 4, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Privia Health Group, Inc. (PRVA).

Where can I read the original DEF 14A filing from Privia Health Group, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Privia Health Group, Inc..

What are the key takeaways from Privia Health Group, Inc.'s DEF 14A?

Privia Health Group, Inc. filed this DEF 14A on April 4, 2024. Key takeaways: Privia Health Group, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 950 N. Glebe Rd., Suite 700, Arlington, VA 22203..

Is Privia Health Group, Inc. a risky investment based on this filing?

Based on this DEF 14A, Privia Health Group, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational distress.

What should investors do after reading Privia Health Group, Inc.'s DEF 14A?

Review the executive compensation details and any shareholder proposals within the DEF 14A to understand potential impacts on corporate governance and shareholder value. The overall sentiment from this filing is neutral.

How does Privia Health Group, Inc. compare to its industry peers?

Privia Health Group operates within the health services industry, focusing on value-based care enablement for physicians.

Are there regulatory concerns for Privia Health Group, Inc.?

As a publicly traded company, Privia Health Group is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings and disclosures.

Industry Context

Privia Health Group operates within the health services industry, focusing on value-based care enablement for physicians.

Regulatory Implications

As a publicly traded company, Privia Health Group is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings and disclosures.

What Investors Should Do

  1. Analyze the executive compensation details for key personnel like Mr. Shawn Morris.
  2. Review any shareholder proposals or director nominations presented in the proxy statement.
  3. Understand the company's rationale for executive pay decisions based on performance metrics.

Key Dates

  • 2024-04-04: Filing of DEF 14A — Submission of the Definitive Proxy Statement to the SEC.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure. No specific comparative data from a previous filing is immediately apparent in this excerpt.

Filing Stats: 4,755 words · 19 min read · ~16 pages · Grade level 11.2 · Accepted 2024-04-04 16:14:52

Filing Documents

Executive Compensation Objectives and Philosophy

Executive Compensation Objectives and Philosophy 35 Determination of Executive Compensation 35 Elements of Compensation 36 Other Policies and Considerations 43 COMPENSATION COMMITTEE REPORT 45

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 46 2023 Summary Compensation Table 46 Grants of Plan-Based Awards in Fiscal 2023 47 Narrative to the Summary Compensation Table and Grants of Plan-Based Awards Table 47 Outstanding Equity Awards at Fiscal Year End Table 50 Options Exercised and Stock Vested in Fiscal 2023 52 Potential Payments Upon Termination or Change in Control 52 Compensation Risk Assessment 53 Equity Compensation Plan Information 54 CEO Pay Ratio 54 Pay Versus Performance Table 56 DIRECTOR COMPENSATION 58

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 60 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 62 OTHER MATTERS 64 APPENDIX A A-1 APPENDIX B B-1 PROXY CARD | 2024 Proxy Statement TOC Table of Contents PROXY STATEMENT SUMMARY QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Why did I receive these materials? The Board of Directors ("Board") is providing these proxy materials to you in connection with the 2024 Annual Meeting of Stockholders ("Annual Meeting"), which will take place on May 22, 2024. The Board is soliciting proxies to be used at the Annual Meeting. These proxy materials were first made available on the Internet on or about April 4, 2024 to all stockholders entitled to vote at the Annual Meeting. What is the purpose of the Annual Meeting? For stockholders to vote on the following proposals: 1. The election of the nominees listed in this proxy statement as Class II directors to serve until our 2027 annual meeting and until their respective successors have been duly elected and qualified. 2. The approval, on an advisory (non-binding) basis, of the compensation of our Named Executive Officers as disclosed in these proxy materials. 3. The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. 4. To approve an amendment to our Charter to remove the supermajority voting provisions relating to amendments to the Charter and the removal of directors. 5. To approve an amendment to our Charter to remove or limit the personal liability of officers to the extent permitted by amendments to the Delaware General Corporation Law. 6. To transact such other business as may properly come before the Annual Meeting. How does the Board of Directors recommend I vote on these proposals? Our Board recommends a vote: "FOR" the election of each of the nominees listed in this proxy sta

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.